<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290196</url>
  </required_header>
  <id_info>
    <org_study_id>EXPAREL</org_study_id>
    <nct_id>NCT03290196</nct_id>
  </id_info>
  <brief_title>The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics</brief_title>
  <official_title>The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrews Research &amp; Education Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Andrews Research &amp; Education Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing shoulder rotator cuff surgery in an outpatient setting are the focus of
      this study. The purpose of this study is to determine if the product EXPAREL® can be used as
      a safe alternative in shoulder surgery to pain pumps, while limiting narcotic use and
      providing appropriate postoperative pain control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on prior research, it is hypothesized EXPAREL® can potentially be used as a local
      anesthetic option after undergoing an arthroscopic rotator cuff repair in the outpatient
      setting. Conducting this study, will allow the option for a surgeon to administer a local
      anesthetic, in a single injection, to the exact location of the surgical procedure and in a
      sterile environment. The purpose of this pilot study is to determine if EXPAREL® can be used
      as a safe alternative to current post-operative pain control methods, while limiting narcotic
      use and providing appropriate postoperative analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 3, 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Log of Pain Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Daily reported patient numeric pain rating</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Log of Narcotic Medication Usage</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of narcotic medication consumed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American Shoulder and Elbow Surgeons Shoulder Score (ASES)</measure>
    <time_frame>2 week follow-up visit</time_frame>
    <description>Pain score measured utilizing patient questionnaire answers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Shoulder and Elbow Surgeons Shoulder Score (ASES)</measure>
    <time_frame>2 week follow-up visit</time_frame>
    <description>Function score measured utilizing patient questionnaire answers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rotator Cuff Tear</condition>
  <arm_group>
    <arm_group_label>EXPAREL 1.3 % in 20 ML Injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:
size of surgical site
volume required to cover the area
individual patient factors that may impact the safety of an amide local anesthetic
maximum doe of 266 mg (20 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL 1.3 % in 20 ML Injection</intervention_name>
    <description>EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.</description>
    <arm_group_label>EXPAREL 1.3 % in 20 ML Injection</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18-72 years of age

          -  Subjects scheduled to undergo a rotator cuff repair with a subacromial decompression
             by one of the protocol investigators

        Exclusion Criteria:

          -  Planned concomitant glenoid labral repair

          -  Previous open shoulder surgery

          -  Neurological deficit or other disability involving the surgical extremity

          -  Anyone with a documented allergy to bupivicaine

          -  Subjects that are not mentally competent to give consent

          -  Pregnant women

          -  Subjects with an intolerance to hydrocodone or oxycodone and/or brand name equivalent
             combination medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Andrews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andrews Institute for Orthopaedics &amp; Sports Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andrews Research &amp; Education Foundation</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson MD, Mickler T, Arthur GR, Rosenburg S, Wilson R. Bupivacaine with and without epinephrine for intercostal nerve block. J Cardiothorac Anesth. 1990 Apr;4(2):200-3.</citation>
    <PMID>2131867</PMID>
  </reference>
  <reference>
    <citation>Colombo G, Padera R, Langer R, Kohane DS. Prolonged duration local anesthesia with lipid-protein-sugar particles containing bupivacaine and dexamethasone. J Biomed Mater Res A. 2005 Nov 1;75(2):458-64.</citation>
    <PMID>16088895</PMID>
  </reference>
  <reference>
    <citation>Bergese SD, Onel E, Morren M, Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med. 2012 Mar-Apr;37(2):145-51. doi: 10.1097/AAP.0b013e31823d0a80.</citation>
    <PMID>22266897</PMID>
  </reference>
  <reference>
    <citation>Portillo J, Kamar N, Melibary S, Quevedo E, Bergese S. Safety of liposome extended-release bupivacaine for postoperative pain control. Front Pharmacol. 2014 Apr 30;5:90. doi: 10.3389/fphar.2014.00090. eCollection 2014. Review.</citation>
    <PMID>24817851</PMID>
  </reference>
  <reference>
    <citation>Candiotti K. Liposomal bupivacaine: an innovative nonopioid local analgesic for the management of postsurgical pain. Pharmacotherapy. 2012 Sep;32(9 Suppl):19S-26S. doi: 10.1002/j.1875-9114.2012.01183.x.</citation>
    <PMID>22956491</PMID>
  </reference>
  <reference>
    <citation>Cohen SM, Vogel JD, Marcet JE, Candiotti KA. Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis. J Pain Res. 2014 Jun 24;7:359-66. doi: 10.2147/JPR.S63764. eCollection 2014.</citation>
    <PMID>25018650</PMID>
  </reference>
  <reference>
    <citation>Bagsby DT, Ireland PH, Meneghini RM. Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. J Arthroplasty. 2014 Aug;29(8):1687-90. doi: 10.1016/j.arth.2014.03.034. Epub 2014 Apr 4.</citation>
    <PMID>24793570</PMID>
  </reference>
  <reference>
    <citation>Singelyn FJ, Lhotel L, Fabre B. Pain relief after arthroscopic shoulder surgery: a comparison of intraarticular analgesia, suprascapular nerve block, and interscalene brachial plexus block. Anesth Analg. 2004 Aug;99(2):589-92, table of contents.</citation>
    <PMID>15271745</PMID>
  </reference>
  <reference>
    <citation>Borgeat A, Ekatodramis G, Kalberer F, Benz C. Acute and nonacute complications associated with interscalene block and shoulder surgery: a prospective study. Anesthesiology. 2001 Oct;95(4):875-80.</citation>
    <PMID>11605927</PMID>
  </reference>
  <reference>
    <citation>Fredrickson MJ, Kilfoyle DH. Neurological complication analysis of 1000 ultrasound guided peripheral nerve blocks for elective orthopaedic surgery: a prospective study. Anaesthesia. 2009 Aug;64(8):836-44. doi: 10.1111/j.1365-2044.2009.05938.x.</citation>
    <PMID>19604186</PMID>
  </reference>
  <reference>
    <citation>Jeng CL, Torrillo TM, Rosenblatt MA. Complications of peripheral nerve blocks. Br J Anaesth. 2010 Dec;105 Suppl 1:i97-107. doi: 10.1093/bja/aeq273. Review.</citation>
    <PMID>21148659</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shoulder</keyword>
  <keyword>Rotator cuff</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Narcotics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

